Clinical-stage biopharmaceutical company focused on developing therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Amylyx Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company specializing in the development of therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Central to its portfolio is AMX0035, a promising dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol, designed to address the underlying mechanisms of ALS.
In addition to its focus on ALS, Amylyx Pharmaceuticals is exploring the potential of AMX0035 for treating other neurodegenerative conditions. This expansion highlights the company's commitment to leveraging its innovative therapeutic approaches to tackle broader challenges in neurology.
Founded in 2013, Amylyx Pharmaceuticals has rapidly established itself as a leader in neurodegenerative disease research and development. With a dedicated team of scientists and clinicians, the company continues to advance its pipeline of novel therapies aimed at improving outcomes and quality of life for patients worldwide.
Driven by a mission to transform the treatment landscape for ALS and beyond, Amylyx Pharmaceuticals remains at the forefront of innovation in biopharmaceuticals. Through strategic partnerships and rigorous scientific endeavors, the company seeks to bring new hope to patients and families affected by neurodegenerative diseases.